UbcH5c-IN-6d
| 中文名称 | UbcH5c-IN-6d |
|---|---|
| 中文同义词 | 化合物 T13242;化合物 UBCH5C-IN-1 |
| 英文名称 | UbcH5c-IN-6d |
| 英文同义词 | UbcH5c-IN-6d;UbcH5c-IN-1;Naphtho[1,2-b]furan-2(3H)-one, 8-[(2-bromophenyl)methoxy]-3a,4,5,9b-tetrahydro-6,9-dimethyl-3-methylene-, (3aS,9bR)-;UbcH5c IN 1,UbcH5cIN1,UbcH-5c-IN-1 |
| CAS号 | 2123480-72-6 |
| 分子式 | C22H21BrO3 |
| 分子量 | 413.3 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 2123480-72-6.mol |
| 结构式 |  |
UbcH5c-IN-6d 性质
| 沸点 | 559.8±50.0 °C(Predicted) |
|---|---|
| 密度 | 1.41±0.1 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 溶于二甲基亚砜 |
| 形态 | Solid |
| 颜色 | White to off-white |
UbcH5c-IN-1 (compound 6d) 是一种有效的、选择性的小分子泛素结合酶 UbcH5c 抑制剂，其与 E2 UbcH5c-IN-1 活性位点Cys85共价结合的 Kd 值为 283 nM，是开发新型类风湿性关节炎药物的先导化合物。
Kd: 283 nM (E2 UbcH5c).
UbcH5c-IN-1 (compound 6d) (5 and 20 mg/kg, p.o., daily, 10-20 days) treatment in Freund’s adjuvant (CFA)-induced adjuvant arthritis (AA) rat model results in appreciable decreases in the arthritis index score and hind paw swelling rate compared with those of the vehicle-treated AA model control group.
| Animal Model: | Freund’s adjuvant (CFA)-induced adjuvant arthritis (AA) rat model. |
| Dosage: | 5 and 20 mg/kg |
| Administration: | Oral administration daily between day 10-20 postimmunization. |
| Result: | Resulted in appreciable decreases in the arthritis index score and hind paw swelling rate compared with those of the vehicle-treated AA model control group. |